Bullish Sign: Zalicus Shareholders Receive Good News

The Burrill Report submits: The new year began with a strong start as one megadeal, a few smaller collaborations, and several venture capital financings were announced.

James Stocklasar Thomas Jr. submits:I venture there is good news on the Zalicus (ZLCS) horizon. Here's why:A report this morning confirms that Zalicus is among those companies like Incyte (INCY) that is collaborating into Novartis' (NVS) sweet spot, i.e. oncology.

By James Stocklasar Thomas Jr.:There was a time when just about no one was as bullish about Zalicus (ZLCS) as I was. I was excited about the ion channel program, the partnership with Novartis (NVS), and the discoveries of their proprietary cHTS-Chalice program.

By James Stocklasar Thomas Jr.:In after-hours, a change in beneficial ownership in Zalicus (ZLCS) showed up on the radar screen.

By James Stocklasar Thomas Jr.:Here in 2012, Zalicus (ZLCS) is re-emerging on the biotech scene as a great investment opportunity offering substantial gains. I have put together this highly investigative report to explain why investors need to get in now. My conclusion is that the share price is very under-valued given the information provided in this report.

Jeremy Richards submits:CombinatoRx (formerly CRXX) recently changed its name to Zalicus (ZLCS) - a healthy positioned biopharmaceutical company with new and existing product developments. Zalicus is considerably undervalued. and should easily be trading double its current stock price.

James Stocklasar Thomas Jr. submits:Over time and study, and a lot of speculation, one wonders with any small biotech, What if? What if we are bought out? Who might that be?

James Stocklasar Thomas Jr. submits:A sign of good news on the horizon? On Wednesday 23 March 2011, Sanofi (SNY) profiled Prednisporin (FOV1101), licensed from Zalicus Inc (ZLCS), as one of its lead Phase 2 drugs in its new ophthalomology division.